Interní Med. 2010; 12(11): 535-539

Myelodysplastic syndrome, its diagnostics and treatment

MUDr.Jana Vondráková, Ph.D.
Hematoonkologická klinika FN Olomouc a LF UP v Olomouci

The present article summarizes current knowledge and the most important information on myelodysplastic syndrome (MDS), its diagnostics

and diferential diagnosis also in consideration of crucial laboratory methods. Then the new classification of this syndrome is mentioned,

that is together with another prognostics systems and factors determinative for the treatment. The therapy includes a lot of possibilities

– supportive care, growth factors of hematopoiesis, immunosuppressive therapy, chemoterapy and stem cells transplantation.

Keywords: myelodysplastic syndrome, diagnostics, treatment, blood count, risk of leukemia development

Published: December 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vondráková J. Myelodysplastic syndrome, its diagnostics and treatment. Interní Med. 2010;12(11):535-539.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Adam Z, Penka M, Doubek M. Myelodysplastický syndrom a myelodysplastické/myeloproliferativní choroby. In Adam Z, a kol. Diagnostické a léčebné postupy u maligních chorob. Grada Publishing, Praha, 2002; 38: 341-350.
    2. Hellström-Lindberg E. Update on supportive care and new therapies: immunomodulatory drugs, growths factors and epigenetic-acting agents. Hematology 2005, ASH Educ. Prog. Book, p. 161-166. Go to original source...
    3. Neuwirtová R. Myelodysplastický syndrom: onkohematologické onemocnění vyššího věku. Čes. Ger. Rev. 2005; 3(2): 21-28.
    4. Indrák K, a kol. Hematologie. Postgraduální klinický projekt. Vnitřní lékařství VII. Praha: Triton, 2006: 278 s.
    5. Bělohlávková P, a kol. Sekundární myelodysplastický syndrom - analýza souboru nemocných. Transfuze Hematol. dnes, 2009; 15(4): 237-243.
    6. Rollison ED, Howlader N, Smith TM, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008; 112(1): 45-52. Go to original source... Go to PubMed...
    7. Čermák J. Myelodysplastický sy. Doporučené postupy pro praktické lékaře. ČLS JEP, projekt MZ ČR, reg. č. o/017/301, dostupný on-line http://www.cls.cz/dp.
    8. Čermák J, Jonášová A. Doporučené diagnostické a léčebné postupy u nemocných s myelodysplastickým syndromem. Praha 2009, Sekce pro MDS ČHS ČLS JEP.
    9. Vondráková J, Zapletalová J, Indráková J, Indrák K. Význam parametrů krevního obrazu pro diagnostiku a odhad prognózy u pacientů s myelodysplastickým syndromem. Praktický lékař 2009; 89(6): 324-327.
    10. Hochová I, Neuwirtová R, Vodičková E, a kol. Myelodysplastický syndrom, Diagnostický atlas. Praha: Jessenius, Maxdorf, 2006: 323 s.
    11. Bennett MJ, Catovsky D, Daniel TM, et al. Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 1982; 51: 189-199. Go to original source... Go to PubMed...
    12. Vardiman WJ, Harris LN, Brunning DR. The Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100(7): 2292-2302. Go to original source... Go to PubMed...
    13. Vardiman JW, et al. The 2008 revision of the Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009: 114 (5). Go to original source... Go to PubMed...
    14. Greenberg P, Cox Ch, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89(6): 2079-2088. Go to original source...
    15. Sperr WR, Wimazal F, Kundi M, et al. Survival analysis and AML development in patients with de novo myelodysplastic syndomes: comparison of six different prognostic scoring systems. Ann Hematol, 2001; 80: 272-277. Go to original source... Go to PubMed...
    16. Čermák J. Erytropoetin v léčbě nemocných s myelodysplastickým syndromem. Vnitřní lékařství 2005; 51(10): 1102-1107.
    17. Jonášová A, Neuwirtová R, Čermák J, et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br. J. Haematol. 1998; 100: 304-309. Go to original source... Go to PubMed...
    18. Deeg JH. Optimization of transplant regimes for patients with myelodysplastic syndrome (MDS). Hematology 2005, ASH Education Program Book, p 167-173, též on-line http://asheducationbook.hematologylibrary.org/. Go to original source...
    19. Vondráková J, Bělohlávková P, Zapletalová J, a kol. Alogenní transplantace krvetvorných buněk u pacientů s myelodysplastickým syndromem a sekundární akutní myeloidní leukemií - retrospektivní analýza. Transfuze Hematol. dnes, 2010; 16(Suppl. 2): 34.

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.